vs
爵士制药（JAZZ）与RUSH ENTERPRISES INC \TX\（RUSHA）财务数据对比。点击上方公司名可切换其他公司
RUSH ENTERPRISES INC \TX\的季度营收约是爵士制药的1.4倍（$1.7B vs $1.2B），爵士制药净利率更高（17.0% vs 3.7%，领先13.3%），爵士制药同比增速更快（10.1% vs -9.0%），RUSH ENTERPRISES INC \TX\自由现金流更多（$411.6M vs $345.8M），过去两年爵士制药的营收复合增速更高（15.2% vs -6.8%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
Rush Enterprises是总部位于美国得克萨斯州新布朗费尔斯的商用车经销商，核心业务是通过旗下Rush Truck Centers销售全新及二手卡车。2019年该公司在全美20个州运营超200家卡车中心，在加拿大设有14个网点，2020年入选财富500强榜单。
JAZZ vs RUSHA — 直观对比
营收规模更大
RUSHA
是对方的1.4倍
$1.2B
营收增速更快
JAZZ
高出19.1%
-9.0%
净利率更高
JAZZ
高出13.3%
3.7%
自由现金流更多
RUSHA
多$65.8M
$345.8M
两年增速更快
JAZZ
近两年复合增速
-6.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.7B |
| 净利润 | $203.5M | $61.7M |
| 毛利率 | — | 20.4% |
| 营业利润率 | 21.2% | 4.9% |
| 净利率 | 17.0% | 3.7% |
| 营收同比 | 10.1% | -9.0% |
| 净利润同比 | 6.5% | 1.8% |
| 每股收益（稀释后） | $3.34 | $0.77 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZRUSHA
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.2B | $1.7B | ||
| Q3 25 | $1.1B | $1.8B | ||
| Q2 25 | $1.0B | $1.8B | ||
| Q1 25 | $897.8M | $1.8B | ||
| Q4 24 | $1.1B | $1.9B | ||
| Q3 24 | $1.1B | $1.8B | ||
| Q2 24 | $1.0B | $1.9B |
净利润JAZZRUSHA
| Q1 26 | — | $61.7M | ||
| Q4 25 | $203.5M | $64.3M | ||
| Q3 25 | $251.4M | $66.7M | ||
| Q2 25 | $-718.5M | $72.4M | ||
| Q1 25 | $-92.5M | $60.3M | ||
| Q4 24 | $191.1M | $74.8M | ||
| Q3 24 | $215.1M | $79.1M | ||
| Q2 24 | $168.6M | $78.7M |
毛利率JAZZRUSHA
| Q1 26 | — | 20.4% | ||
| Q4 25 | — | 20.8% | ||
| Q3 25 | — | 21.0% | ||
| Q2 25 | — | 20.7% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 21.0% | ||
| Q2 24 | — | 20.2% |
营业利润率JAZZRUSHA
| Q1 26 | — | 4.9% | ||
| Q4 25 | 21.2% | 5.5% | ||
| Q3 25 | 5.1% | 5.6% | ||
| Q2 25 | -65.6% | 6.0% | ||
| Q1 25 | -6.2% | 5.2% | ||
| Q4 24 | 17.5% | 5.8% | ||
| Q3 24 | 24.7% | 6.7% | ||
| Q2 24 | 19.5% | 6.4% |
净利率JAZZRUSHA
| Q1 26 | — | 3.7% | ||
| Q4 25 | 17.0% | 3.8% | ||
| Q3 25 | 22.3% | 3.7% | ||
| Q2 25 | -68.7% | 3.9% | ||
| Q1 25 | -10.3% | 3.4% | ||
| Q4 24 | 17.6% | 3.9% | ||
| Q3 24 | 20.4% | 4.4% | ||
| Q2 24 | 16.5% | 4.1% |
每股收益（稀释后）JAZZRUSHA
| Q1 26 | — | $0.77 | ||
| Q4 25 | $3.34 | $0.81 | ||
| Q3 25 | $4.08 | $0.83 | ||
| Q2 25 | $-11.74 | $0.90 | ||
| Q1 25 | $-1.52 | $0.73 | ||
| Q4 24 | $2.97 | $-95.13 | ||
| Q3 24 | $3.42 | $0.97 | ||
| Q2 24 | $2.49 | $97.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | — |
| 总债务越低越好 | $5.4B | $277.8M |
| 股东权益账面价值 | $4.3B | $2.3B |
| 总资产 | $11.7B | $4.5B |
| 负债/权益比越低杠杆越低 | 1.24× | 0.12× |
8季度趋势，按日历期对齐
现金及短期投资JAZZRUSHA
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $212.6M | ||
| Q3 25 | $1.3B | $242.0M | ||
| Q2 25 | $1.2B | $211.1M | ||
| Q1 25 | $1.9B | $228.7M | ||
| Q4 24 | $2.4B | $228.1M | ||
| Q3 24 | $2.2B | $185.1M | ||
| Q2 24 | $1.4B | $167.3M |
总债务JAZZRUSHA
| Q1 26 | — | $277.8M | ||
| Q4 25 | $5.4B | $274.8M | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | $408.4M | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — |
股东权益JAZZRUSHA
| Q1 26 | — | $2.3B | ||
| Q4 25 | $4.3B | $2.2B | ||
| Q3 25 | $4.0B | $2.2B | ||
| Q2 25 | $3.7B | $2.2B | ||
| Q1 25 | $4.2B | $2.2B | ||
| Q4 24 | $4.1B | $2.1B | ||
| Q3 24 | $4.2B | $2.1B | ||
| Q2 24 | $3.8B | $2.0B |
总资产JAZZRUSHA
| Q1 26 | — | $4.5B | ||
| Q4 25 | $11.7B | $4.4B | ||
| Q3 25 | $11.4B | $4.6B | ||
| Q2 25 | $10.9B | $4.7B | ||
| Q1 25 | $11.5B | $4.7B | ||
| Q4 24 | $12.0B | $4.6B | ||
| Q3 24 | $12.3B | $4.6B | ||
| Q2 24 | $11.4B | $4.5B |
负债/权益比JAZZRUSHA
| Q1 26 | — | 0.12× | ||
| Q4 25 | 1.24× | 0.12× | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | 0.19× | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | — |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $411.6M |
| 自由现金流率自由现金流/营收 | 28.9% | 24.4% |
| 资本支出强度资本支出/营收 | 1.4% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.78× | — |
| 过去12个月自由现金流最近4个季度 | $1.3B | $828.4M |
8季度趋势，按日历期对齐
经营现金流JAZZRUSHA
| Q1 26 | — | — | ||
| Q4 25 | $362.5M | $112.9M | ||
| Q3 25 | $474.6M | $367.8M | ||
| Q2 25 | $88.9M | $227.6M | ||
| Q1 25 | $429.8M | $153.5M | ||
| Q4 24 | $398.6M | $392.3M | ||
| Q3 24 | $398.7M | $111.7M | ||
| Q2 24 | $331.4M | $270.6M |
自由现金流JAZZRUSHA
| Q1 26 | — | $411.6M | ||
| Q4 25 | $345.8M | $31.9M | ||
| Q3 25 | $459.4M | $271.2M | ||
| Q2 25 | $75.9M | $113.8M | ||
| Q1 25 | $415.9M | $45.1M | ||
| Q4 24 | $385.3M | $263.5M | ||
| Q3 24 | $388.0M | $-20.0M | ||
| Q2 24 | $324.3M | $177.2M |
自由现金流率JAZZRUSHA
| Q1 26 | — | 24.4% | ||
| Q4 25 | 28.9% | 1.9% | ||
| Q3 25 | 40.8% | 15.2% | ||
| Q2 25 | 7.3% | 6.2% | ||
| Q1 25 | 46.3% | 2.6% | ||
| Q4 24 | 35.4% | 13.7% | ||
| Q3 24 | 36.8% | -1.1% | ||
| Q2 24 | 31.7% | 9.1% |
资本支出强度JAZZRUSHA
| Q1 26 | — | 2.0% | ||
| Q4 25 | 1.4% | 4.8% | ||
| Q3 25 | 1.3% | 5.4% | ||
| Q2 25 | 1.2% | 6.2% | ||
| Q1 25 | 1.5% | 6.2% | ||
| Q4 24 | 1.2% | 6.7% | ||
| Q3 24 | 1.0% | 7.3% | ||
| Q2 24 | 0.7% | 4.8% |
现金转化率JAZZRUSHA
| Q1 26 | — | — | ||
| Q4 25 | 1.78× | 1.75× | ||
| Q3 25 | 1.89× | 5.51× | ||
| Q2 25 | — | 3.14× | ||
| Q1 25 | — | 2.55× | ||
| Q4 24 | 2.09× | 5.25× | ||
| Q3 24 | 1.85× | 1.41× | ||
| Q2 24 | 1.97× | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RUSHA
| New and used commercial vehicle sales | $955.1M | 57% |
| Aftermarket products and services sales | $627.2M | 37% |
| Lease and rental sales | $92.3M | 5% |
| Finance and insurance | $5.6M | 0% |
